Maurie is the Non-Executive Chairman of Aeris Environmental Ltd (ASX:AEI). He has a 30-year track record of building successful companies in the Australasian healthcare market and is recognised as one of its most respected business executives. Maurie has significant experience and an extensive network within the life-sciences, pharmaceutical and finance sectors, both in Australia and internationally. He is a Principal of GryphonCapital, an independent investment house that facilitates the financing and development of emerging healthcare-related entities. Maurie is the Non-Executive Chairman of Nanosonics Limited (ASX:NAN) and the Non-Executive Deputy Chairman of Vectus Biosystems Limited (ASX:VBS), both of which are Australian Securities Exchange listed public companies. He is also a Founder and Director of Henry Schein Halas, a joint venture with the NASDAQ listed Henry Schein, Inc., the leading supplier of healthcare products in Australasia. Maurie is a Director of Novapharm Research and of Regional Health Care Group, along with other varied interests. Director since 2002 – appointed Chairman 2002.

Steven M.Sc from the UNSW in the field of Polymer Chemistry is a Non-Executive Director of Aeris Environmental Ltd (ASX:AEI). He is the Technical Director of Novapharm Research. Steven has over 40 years of experience in commercial R&D in the areas of pharmaceutical, medical, cosmetic and specialty industrial products. Under his technical direction, Novapharm Research has become a world-leader in infection control science. Steven holds a number of international patents. Director since 2002.

Bernard B.Arch is a Non-Executive Director of Aeris Environmental Ltd (ASX:AEI). He is a Co-Founder and Director of the Regional Health Care Group of companies. Bernard serves as the Chief Executive Officer of Stangcorp Pty Ltd, Stoneville Ltd and Brunswick Property Pty Ltd, which are key property entities in the Stang Group. He manages a broad portfolio of investments in the private and listed sectors, and has enjoyed over 40 years of operational leadership in successful healthcare businesses. Bernard serves as a Director of Novapharm Research. He is a Director of Weizmann Australia, which represents the Weizmann Institute of Science in Australia, and the Institute has recently established the Garvan-Weizmann Centre of Cellular Genomics in Sydney, in joint venture with the Garvan Institute. Bernard served as a Non-Executive Director of Nanosonics Limited (ASX:NAN) until 2007 and as a Non-Executive Director of Vectus Biosystems Limited (ASX:VBS) until late 2016. Director since 2002.

Alex M.Sc, majoring in Chemical Engineering, PhD in Physical Chemistry is a Non-Executive Director of Aeris Environmental Ltd (ASX:AEI).  Earlier in his career, he spent seven years with the Institute of Semiconductors in Ukraine and four years as a Vice President of New York-based MicroMax Computer Intelligence Inc.  Alex has had extensive experience in research and development, holds over 100 international patents and has authored over 50 scientific articles.  He has previously made a substantial contribution to the success of Nanosonics Limited, and has successfully developed and commercialised several revolutionary technologies across many international markets.  Alex has scientific, regulatory and commercial experience.  Director since 3 October 2016.

Peter B.Com, CA is the Chief Executive Officer, Alternate Director for M and B Stang, and Chief Financial Officer, of Aeris Environmental Ltd (ASX:AEI). He is a Non-Executive Director of Vectus Biosystems Limited (ASX:VBS). Peter previously acted as the Chief Financial Officer and Company Secretary of Vectus and Accugen Pty Limited. He is also an Executive Director and the Chief Financial Officer of The Regional Health Care Group and GryphonCapital. Regional Health Care Group is a diversified healthcare product supplier, with successful businesses across a range of medical, pharmaceutical, consumer healthcare, and research and development sectors. GryphonCapital is an independent investment house that facilitates the financing and development of emerging healthcare-related entities. Peter began his career working for five years at BDO, a global accounting and consulting firm, then has since spent several years working in industry. He holds a number of private directorships and board positions. Alternate Director since 2011.

Robert BEc, CA, FCIS, FFin, FAICD was appointed to the position of Company Secretary of Aeris Environmental Ltd (ASX:AEI) in 2002. His experience has been gained over 40 years in financial and corporate roles, including over 25 years in company secretarial roles for ASX-listed companies and over 19 years as a Director of ASX-listed companies. Robert has over 30 years of experience in industry and, prior to that, spent 10 years with an international firm of chartered accountants. He is a director of Oakhill Hamilton Pty Ltd, which provides secretarial and corporate advisory services to a range of listed and unlisted companies. Robert is also presently the Company Secretary of ASX-listed companies Nanosonics Limited, Vectus Biosystems Limited, Brain Resource Limited and Xref Limited.